chartexchange

BTAI
BioXcel Therapeutics, Inc. Common Stock
stockNASDAQ

InactiveSep 4, 2026 1:00:00 AM EDT
0.0739USD-37.106%(-0.0436)47,480,719
Loading…
Loading…
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New Haven, Connecticut, USA
Feb 10, 2025 · 1-for-16 (reverse)
BTAI Profile

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

BTAI Performance
PeriodPriceDateChange